(19)
(11) EP 2 525 817 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.09.2017 Bulletin 2017/38

(45) Mention of the grant of the patent:
09.08.2017 Bulletin 2017/32

(21) Application number: 11735230.2

(22) Date of filing: 21.01.2011
(51) International Patent Classification (IPC): 
A61K 39/145(2006.01)
(86) International application number:
PCT/US2011/022062
(87) International publication number:
WO 2011/091255 (28.07.2011 Gazette 2011/30)

(54)

VACCINE VECTORS AND METHODS OF ENHANCING IMMUNE RESPONSES

IMPFSTOFFVEKTOREN UND VERFAHREN ZUR VERSTÄRKUNG VON IMMUNREAKTIONEN

VECTEURS DE VACCIN ET PROCÉDÉS D'AMPLIFICATION DE RÉPONSES IMMUNITAIRES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 21.01.2010 US 297098 P

(43) Date of publication of application:
28.11.2012 Bulletin 2012/48

(73) Proprietors:
  • The Board of Trustees of The University of Arkansas
    Little Rock, AR 72207 (US)
  • The Texas A&M University System
    College Station, TX 77843-3369 (US)

(72) Inventors:
  • BERGHMAN, Luc
    College Station, TX 77845 (US)
  • BOTTJE, Walter
    Fayetteville, AR 72703 (US)
  • HARGIS, Billy
    Fayetteville, AR 72764 (US)
  • LAYTON, Sherryll
    Rogers, AR 72758 (US)

(74) Representative: Kremer, Simon Mark et al
Mewburn Ellis LLP
City Tower 40 Basinghall Street London EC2V 5DE
City Tower 40 Basinghall Street London EC2V 5DE (GB)


(56) References cited: : 
WO-A2-2008/036675
US-A1- 2003 165 538
US-A1- 2008 030 520
US-A1- 2008 305 120
 WO-A2-2008/036675
US-A1- 2008 004 207
US-A1- 2008 069 821
   
  • KIMURA R ET AL: "Enhancement of antibody response by high mobility group box protein-1-based DNA immunization", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 361, no. 1-2, 30 September 2010 (2010-09-30), pages 21-30, XP027301012, ISSN: 0022-1759 [retrieved on 2010-05-12]
  • MAURIELLO E M F ET AL: "Display of heterologous antigens on the Bacillus subtilis spore coat using CotC as a fusion partner", VACCINE, ELSEVIER LTD, GB, vol. 22, no. 9-10, 12 March 2004 (2004-03-12), pages 1177-1187, XP004493381, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2003.09.031
  • SAENZ R ET AL: "HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 47, 3 November 2010 (2010-11-03), pages 7556-7562, XP027434019, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2010.08.054 [retrieved on 2010-08-25]
  • ROVERE-QUERINI ET AL.: 'HMGB1 is an endogenous immune adjuvant released by necrotic cells.' EMBO REP vol. 5, no. 8, August 2004, pages 825 - 830
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).